VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Sweis on Trend Toward Immunotherapy in GU Malignancies

Randy F. Sweis, MD
Published: Monday, Oct 03, 2016



Randy F. Sweis, MD, clinical instructor, University of Chicago Medicine, discusses the emerging field of immunotherapy to treat patients with genitourinary (GU) malignancies.

GU cancers has had an interesting course of history, Sweis explains. While bacillus Calmette-Guérin is a standard immunotherapy that has long been available for patients with bladder cancer, Sweis says there was a lull in bladder cancer for quite some time. In kidney cancer, there was drug development with tyrosine kinase inhibitors, and in prostate cancer, patients have treatment options including androgen-targeted agents. However, bladder cancer remained quiet regarding FDA-approved drugs until the May 2016 approval of the PD-L1 inhibitor atezolizumab (Tecentriq).

Now, it is an exciting time to see anti–PD-1 therapies taking off in bladder cancer and renal cell carcinoma, where nivolumab (Opdivo) has also been approved as a treatment for patients.


Randy F. Sweis, MD, clinical instructor, University of Chicago Medicine, discusses the emerging field of immunotherapy to treat patients with genitourinary (GU) malignancies.

GU cancers has had an interesting course of history, Sweis explains. While bacillus Calmette-Guérin is a standard immunotherapy that has long been available for patients with bladder cancer, Sweis says there was a lull in bladder cancer for quite some time. In kidney cancer, there was drug development with tyrosine kinase inhibitors, and in prostate cancer, patients have treatment options including androgen-targeted agents. However, bladder cancer remained quiet regarding FDA-approved drugs until the May 2016 approval of the PD-L1 inhibitor atezolizumab (Tecentriq).

Now, it is an exciting time to see anti–PD-1 therapies taking off in bladder cancer and renal cell carcinoma, where nivolumab (Opdivo) has also been approved as a treatment for patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary MalignanciesMay 30, 20181.5
Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field ForwardMay 30, 20181.5
Publication Bottom Border
Border Publication
x